Lineage Cell Therapeutics (LCTX) to Release Earnings on Thursday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $1.8420 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Lineage Cell Therapeutics had a negative net margin of 434.44% and a negative return on equity of 89.36%. The business had revenue of $1.73 million during the quarter, compared to analysts’ expectations of $3.60 million. On average, analysts expect Lineage Cell Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Lineage Cell Therapeutics Stock Up 0.9%

Shares of LCTX opened at $1.12 on Wednesday. Lineage Cell Therapeutics has a 52 week low of $0.95 and a 52 week high of $2.09. The company has a market capitalization of $279.22 million, a price-to-earnings ratio of -3.86 and a beta of 1.53. The stock’s 50-day moving average price is $1.22 and its 200-day moving average price is $1.46.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in LCTX. Marshall Wace LLP purchased a new stake in shares of Lineage Cell Therapeutics during the fourth quarter worth approximately $2,275,000. Goldman Sachs Group Inc. raised its stake in Lineage Cell Therapeutics by 894.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,438,746 shares of the company’s stock valued at $2,403,000 after purchasing an additional 1,294,070 shares during the last quarter. Jane Street Group LLC lifted its holdings in Lineage Cell Therapeutics by 494.7% in the 4th quarter. Jane Street Group LLC now owns 1,004,794 shares of the company’s stock valued at $1,678,000 after purchasing an additional 835,831 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Lineage Cell Therapeutics by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,006,930 shares of the company’s stock valued at $15,222,000 after purchasing an additional 524,057 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Lineage Cell Therapeutics by 26.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,404,800 shares of the company’s stock valued at $4,016,000 after purchasing an additional 499,167 shares in the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $3.00 price target on shares of Lineage Cell Therapeutics in a report on Monday, May 4th. Canaccord Genuity Group began coverage on Lineage Cell Therapeutics in a research report on Tuesday, April 28th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Tuesday, July 14th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $6.25.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.